Literature DB >> 23456450

Exercise capacity and quality of life in patients with schizophrenia.

Arno Kerling1, Uwe Tegtbur, Marc Ziegenbein, Lena Grams, Dirk Robert Heinze, Marcel Sieberer.   

Abstract

The aim of this study was to resolve the relationship between physical capacity (PC) and quality of life (Qol) in schizophrenic patients and healthy controls. 31 patients (PG: 18 male, 13 female) and a control group (CG) of 50 healthy subjects (15 male, 35 female) were involved. PC was assessed as peak oxygen uptake [VO2peak, (ml (min kgKG)(-1))] and power output expressed as watts per kilogram (W kg(-1)). Qol was assessed using the SF-36 questionnaire. Patients with schizophrenia showed reduced VO2peak (male: PG 29 ± 5 vs. CG 44 ± 10; female: PG 21 ± 4 vs. CG 30 ± 8) and power output (male: PG 2.04 ± 0.47 vs. CG 3.43 ± 0.70; female PG 1.40 ± 0.28 vs. CG 2.43 ± 0.52). Scales of the SF-36 questionnaire were lower in the PG. While in the CG correlations were found between PC and several subscales of Qol, this was not the case in the PG. The restricted PC seen in the PG showed no relation to their subjectively assessed worsened Qol, which would indicate that schizophrenic patients evaluate limitations arising from this differently than healthy control subjects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456450     DOI: 10.1007/s11126-013-9256-4

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  28 in total

1.  Physical inactivity: the biggest public health problem of the 21st century.

Authors:  Steven N Blair
Journal:  Br J Sports Med       Date:  2009-01       Impact factor: 13.800

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Body mass index, waist circumference and quality of life in individuals with schizophrenia.

Authors:  Guy Faulkner; Tony Cohn; Gary Remington; Hyacinth Irving
Journal:  Schizophr Res       Date:  2006-11-30       Impact factor: 4.939

4.  The unhealthy lifestyle of people with schizophrenia.

Authors:  S Brown; J Birtwistle; L Roe; C Thompson
Journal:  Psychol Med       Date:  1999-05       Impact factor: 7.723

Review 5.  Metabolic risk during antipsychotic treatment.

Authors:  John W Newcomer
Journal:  Clin Ther       Date:  2004-12       Impact factor: 3.393

6.  The impact of weight gain on quality of life among persons with schizophrenia.

Authors:  David B Allison; Joan A Mackell; Diana D McDonnell
Journal:  Psychiatr Serv       Date:  2003-04       Impact factor: 3.084

7.  [Assessment of health related quality of life with the SF-36 Health Survey].

Authors:  M Bullinger
Journal:  Rehabilitation (Stuttg)       Date:  1996-08       Impact factor: 1.113

Review 8.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

Review 9.  Physical illness and schizophrenia: a review of the literature.

Authors:  S Leucht; T Burkard; J Henderson; M Maj; N Sartorius
Journal:  Acta Psychiatr Scand       Date:  2007-11       Impact factor: 6.392

10.  Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study.

Authors:  Eric Tran; Frédéric Rouillon; Jean-Yves Loze; Françoise Casadebaig; Alain Philippe; Fabien Vitry; Frédéric Limosin
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

View more
  2 in total

Review 1.  Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-07-15       Impact factor: 3.911

2.  Endurance training in patients with schizophrenia and healthy controls: differences and similarities.

Authors:  Katriona Keller-Varady; Alkomiet Hasan; Thomas Schneider-Axmann; Ursula Hillmer-Vogel; Björn Adomßent; Thomas Wobrock; Andrea Schmitt; Andree Niklas; Peter Falkai; Berend Malchow
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-05       Impact factor: 5.270

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.